CA2853415C - 18f - fluciclovine compositions in citrate buffers - Google Patents

18f - fluciclovine compositions in citrate buffers Download PDF

Info

Publication number
CA2853415C
CA2853415C CA2853415A CA2853415A CA2853415C CA 2853415 C CA2853415 C CA 2853415C CA 2853415 A CA2853415 A CA 2853415A CA 2853415 A CA2853415 A CA 2853415A CA 2853415 C CA2853415 C CA 2853415C
Authority
CA
Canada
Prior art keywords
formula
facbc
compound
pharmaceutical composition
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2853415A
Other languages
English (en)
French (fr)
Other versions
CA2853415A1 (en
Inventor
Kristine ROMOREN
Olav Ryan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare Ltd
Original Assignee
GE Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2011/073670 external-priority patent/WO2012089594A1/en
Application filed by GE Healthcare Ltd filed Critical GE Healthcare Ltd
Publication of CA2853415A1 publication Critical patent/CA2853415A1/en
Application granted granted Critical
Publication of CA2853415C publication Critical patent/CA2853415C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0406—Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2853415A 2011-12-21 2012-12-21 18f - fluciclovine compositions in citrate buffers Active CA2853415C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2011/073670 2011-12-21
PCT/EP2011/073670 WO2012089594A1 (en) 2010-12-29 2011-12-21 Eluent solution
PCT/EP2012/076689 WO2013093025A1 (en) 2011-12-21 2012-12-21 18f - fluciclovine compositions in citrate buffers

Publications (2)

Publication Number Publication Date
CA2853415A1 CA2853415A1 (en) 2013-06-27
CA2853415C true CA2853415C (en) 2020-11-17

Family

ID=47436002

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2853415A Active CA2853415C (en) 2011-12-21 2012-12-21 18f - fluciclovine compositions in citrate buffers

Country Status (15)

Country Link
US (1) US20150231249A1 (enExample)
EP (1) EP2793954B1 (enExample)
JP (1) JP6446268B2 (enExample)
KR (1) KR20140102700A (enExample)
CN (2) CN109966515A (enExample)
AU (1) AU2012356846B2 (enExample)
CA (1) CA2853415C (enExample)
ES (1) ES2841109T3 (enExample)
GB (1) GB2509476B (enExample)
IL (1) IL232397A (enExample)
IN (1) IN2014DN03245A (enExample)
PL (1) PL2793954T3 (enExample)
RU (1) RU2623163C2 (enExample)
SG (1) SG11201403412YA (enExample)
WO (1) WO2013093025A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11534494B2 (en) 2011-12-21 2022-12-27 Ge Healthcare Limited Formulation and method of synthesis
GB201411569D0 (en) * 2014-06-30 2014-08-13 Ge Healthcare Ltd Novel formulation and method of synthesis
GB201305687D0 (en) * 2013-03-28 2013-05-15 Ge Healthcare Ltd Radiolabelling process
GB202005282D0 (en) 2020-04-09 2020-05-27 Blue Earth Diagnostics Ltd Pharmaceutical Formulations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1356827A1 (en) * 2002-04-24 2003-10-29 Mallinckrodt Inc. Method for obtaining a 2-18F-fluor-2-deoxy-D-glucose (18F-FDG)-solution
US7993626B2 (en) * 2007-01-11 2011-08-09 Immunomedics, Inc. Methods and compositions for F-18 labeling of proteins, peptides and other molecules
BR0215913A (pt) 2002-11-05 2005-08-09 Ion Beam Applic Sa Composição de radiofármacos rotulados com 18-f e processo para obtê-los
CN100418585C (zh) * 2003-07-24 2008-09-17 伯拉考成像股份公司 稳定的放射性药物组合物及制备方法
GB0422004D0 (en) * 2004-10-05 2004-11-03 Amersham Plc Method of deprotection
RU2428415C2 (ru) * 2005-11-29 2011-09-10 Нихон Меди-Физикс Ко., Лтд. Соединение-предшественник органического соединения, меченного радиоактивным галогеном
US7897811B2 (en) * 2006-05-11 2011-03-01 Nihon Medi-Physics Co., Ltd. Process for production of radioactive fluorine-labeled organic compound
US20100056826A1 (en) 2006-11-09 2010-03-04 Nihon Medi-Physicis Co., Ltd. Radioactive diagnostic imaging agent
US8790620B2 (en) * 2006-12-21 2014-07-29 Nihon Medi-Physics Co., Ltd. Radioactive diagnostic imaging agent
EP2119458B9 (en) * 2007-02-13 2013-08-21 Nihon Medi-Physics Co., Ltd. Method for production of radiation diagnostic imaging agent
KR20130132892A (ko) * 2010-12-29 2013-12-05 지이 헬쓰케어 리미티드 용리제 용액

Also Published As

Publication number Publication date
AU2012356846A1 (en) 2014-06-05
GB2509476B (en) 2018-08-08
CA2853415A1 (en) 2013-06-27
SG11201403412YA (en) 2014-07-30
JP6446268B2 (ja) 2018-12-26
EP2793954B1 (en) 2020-10-21
EP2793954A1 (en) 2014-10-29
IN2014DN03245A (enExample) 2015-07-10
CN103998065A (zh) 2014-08-20
RU2014118755A (ru) 2016-02-10
US20150231249A1 (en) 2015-08-20
WO2013093025A1 (en) 2013-06-27
GB201408239D0 (en) 2014-06-25
IL232397A0 (en) 2014-06-30
IL232397A (en) 2016-12-29
PL2793954T3 (pl) 2021-04-06
ES2841109T3 (es) 2021-07-07
RU2623163C2 (ru) 2017-06-22
AU2012356846B2 (en) 2017-07-27
JP2015500865A (ja) 2015-01-08
GB2509476A (en) 2014-07-02
KR20140102700A (ko) 2014-08-22
CN109966515A (zh) 2019-07-05

Similar Documents

Publication Publication Date Title
EP3766522B1 (en) Automated method for the preparation of 18f-fluciclovine compositions
CA2953641C (en) Novel formulation and method of synthesis
US10023525B2 (en) Preparation of 18F-fluciclovine
AU2012356846B2 (en) 18F - Fluciclovine compositions in citrate buffers
US11534494B2 (en) Formulation and method of synthesis
CA2908029A1 (en) Radiolabelling process
GB2561122B (en) Composition comprising [18F]-Fluciclovine
HK40011012A (en) 18f - fluciclovine compositions in citrate buffers
US20220001034A1 (en) Novel formulation and method of synthesis
NZ624250A (en) 18f-fluciclovine compositions in citrate buffers
NZ624250B2 (en) 18f-fluciclovine compositions in citrate buffers
HK1197368A (en) 18f - fluciclovine compositions in citrate buffers
HK1234386B (en) Novel formulation and method of synthesis

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20171129

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241209

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241209

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251119

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251119